Plus Therapeutics
PSTV
PSTV was delisted on the 31st of July, 2026.
6 hedge funds and large institutions have $4.51M invested in Plus Therapeutics in 2017 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and closing their positions.
50% more funds holding
Funds holding: 4 → 6 (+2)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% less capital invested
Capital invested by funds: $4.51M → $4.51M (-$6.07K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$606K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$404K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$202K |
| 4 |
Renaissance Technologies
New York
|
+$202K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$202K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$74K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$73K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$25K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FDCDDQ
26
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $146 | – | – | – |
|
|
27
Citadel Advisors
Miami,
Florida
| – | -$25K | – | – |
|
|
28
Jacobs Levy Equity Management
Florham Park,
New Jersey
| – | -$74K | – | – |
|
|
VKH
29
Virtu KCG Holdings
New York
| – | -$73K | – | – |
|
PSTV Hedge Fund Activity: Q2 2017 in Review
6 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q2 2017, worth a combined $4.51M — down 0.13% from $4.51M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new PSTV positions and 0 closed out — a net gain of 2 holders — while 3 added to existing stakes and 0 trimmed.
The largest buyer was Perkins Capital Management, adding an estimated $606K. The largest seller was Jacobs Levy Equity Management, cutting an estimated $74K.
- 6 institutional investors held Plus Therapeutics (PSTV) as of Q2 2017, up from 4 in Q1 2017.
- Funds reported $4.51M of Plus Therapeutics stock for Q2 2017, down 0.13% quarter-over-quarter.
- 2 funds opened new Plus Therapeutics positions in Q2 2017 and 0 closed out, a net change of +2 holders.
- The largest Plus Therapeutics buyer in Q2 2017 was Perkins Capital Management, an estimated $606K added.
- The largest Plus Therapeutics seller in Q2 2017 was Jacobs Levy Equity Management, an estimated $74K sold.
Based on aggregated 13F filings for Q2 2017.